Literature DB >> 34766301

CPP Applications in Immune Modulation and Disease Therapy.

Ja-Hyun Koo1,2, Won-Ju Kim1,2, Je-Min Choi3,4,5.   

Abstract

About 30 years ago, the discovery of CPP improved the therapeutic approach to treat diseases and extended the range of potential targets to intracellular molecules. There are potential drug candidates for FDA approval based on active studies in basic research, preclinical, and clinical trials. Various attempts by CPP application to control the diseases such as allergy, autoimmunity, cancer, and infection demonstrated a strategy to make a new drug pipeline for successful discovery of a biologic drug for immune modulation. However, there are still no CPP-based drug candidates for immune-related diseases in the clinical stage. To control immune responses successfully, not only increasing delivery efficiency of CPPs but also selecting potential target cells and cargoes could be important issues. In particular, as it becomes possible to control intracellular targets, efforts to find various novel potential target are being attempted. In this chapter, we focused on CPP-based approaches to treat diseases through modulation of immune responses and discussed for perspectives on future direction of the research for successful application of CPP technology to immune modulation and disease therapy in clinical trial.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Allergy; Autoimmune disease; Cancer; Clinical trials; Disease therapy; Immune cells; Immune modulation; Neurological disease; Vaccine

Mesh:

Substances:

Year:  2022        PMID: 34766301     DOI: 10.1007/978-1-0716-1752-6_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  85 in total

Review 1.  Cell-Penetrating Peptides: From Basic Research to Clinics.

Authors:  Giulia Guidotti; Liliana Brambilla; Daniela Rossi
Journal:  Trends Pharmacol Sci       Date:  2017-02-14       Impact factor: 14.819

2.  Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

3.  Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use.

Authors:  C Emmons; L G Hunsicker
Journal:  Iowa Med       Date:  1987-02

4.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

5.  Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation.

Authors:  J B Rothbard; S Garlington; Q Lin; T Kirschberg; E Kreider; P L McGrane; P A Wender; P A Khavari
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

6.  Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex.

Authors:  M J May; F D'Acquisto; L A Madge; J Glöckner; J S Pober; S Ghosh
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

7.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.

Authors:  P A Wender; D J Mitchell; K Pattabiraman; E T Pelkey; L Steinman; J B Rothbard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.

Authors:  Tiziana Borsello; Peter G H Clarke; Lorenz Hirt; Alessandro Vercelli; Mariaelena Repici; Daniel F Schorderet; Julien Bogousslavsky; Christophe Bonny
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

9.  Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness-A Double-blind, Randomized, Placebo-controlled Phase 3 Study.

Authors:  Hinrich Staecker; Galina Jokovic; Sergey Karpishchenko; Andrea Kienle-Gogolok; Andrzej Krzyzaniak; Chia-Der Lin; Pavel Navratil; Ventzislav Tzvetkov; Nida Wright; Thomas Meyer
Journal:  Otol Neurotol       Date:  2019-06       Impact factor: 2.311

Review 10.  Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application.

Authors:  Jing Xie; Ye Bi; Huan Zhang; Shiyan Dong; Lesheng Teng; Robert J Lee; Zhaogang Yang
Journal:  Front Pharmacol       Date:  2020-05-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.